Search

Displaying results 8131 - 8140 of 8389 in total
  1. Drug

    Capravirine

    go.drugbank.com/drugs/DB08502
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Substrates
  2. Drug

    Cabozantinib

    go.drugbank.com/drugs/DB08875
    ApprovedInvestigational

    Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Inhibitors
  3. Drug

    Isoliquiritigenin

    go.drugbank.com/drugs/DB03285
    Experimental

    Isoliquiritigenin is a precursor to several flavonones in many plants.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  4. Drug

    Rhodamine 6G

    go.drugbank.com/drugs/DB03825
    Investigational

    Categories: P-glycoprotein substrates
  5. Drug

    Azosemide

    go.drugbank.com/drugs/DB08961
    Investigational

    Azosemide is a loop diuretic used to treat hypertension, edema, and ascites.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  6. Drug

    Glibornuride

    go.drugbank.com/drugs/DB08962
    ApprovedWithdrawn

    Glibornuride is a sulfonylurea-type anti-diabetic drug.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  7. Drug

    Fluprednidene

    go.drugbank.com/drugs/DB08970
    Experimental

    Fluprednidene is a corticosteroid.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  8. Drug

    Flumequine

    go.drugbank.com/drugs/DB08972
    ApprovedWithdrawn

    Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections.

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  9. Drug

    Suvorexant

    go.drugbank.com/drugs/DB09034
    ApprovedInvestigational

    Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  10. Drug

    Lenvatinib

    go.drugbank.com/drugs/DB09078
    ApprovedInvestigational

    Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that ...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates